ACE Inhibitors News and Research

RSS

ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.

Left ventricular systolic dysfunction prevalent in at-risk inpatients

Asymptomatic left ventricular systolic dysfunction is present in about 5% of general medical inpatients who have at least one risk factor for heart failure, research shows.

14 Jan 2013

NSAID–antihypertensive combinations may risk kidney damage

Physicians should be aware that treating patients with a combination of antihypertensives along with nonsteroidal anti-inflammatory drugs may cause kidney damage, say researchers.

14 Jan 2013

Diuretic-based antihypertensive therapy touted for obese

Diuretic-based antihypertensive regimens may be preferable to calcium channel blocker-based therapy in patients who are obese, suggest researchers writing in The Lancet.

24 Dec 2012

Diuretic-based antihypertensive therapy touted for obese

Diuretic-based antihypertensive regimens may be preferable to calcium channel blocker-based therapy in patients who are obese, suggest researchers writing in The Lancet.

13 Dec 2012

BMI may influence which blood pressure treatments work best

According to new research published Online First in The Lancet, body mass index (BMI) may influence which blood pressure medications work best at reducing the major complications of high blood pressure (strokes, heart attacks, and death).

7 Dec 2012

$ACE-inhibitors, angiotensin receptor blockers can treat heart failure with preserved ejection fraction$

ACE-inhibitors, angiotensin receptor blockers can treat heart failure with preserved ejection fraction

A novel study from Karolinska Institutet in Sweden suggests that commonly used drugs to treat heart failure and high blood pressure may have a wider range of application than earlier known, and also can be used against so called HFPEF - a type of heart failure that until now has been impossible to treat.

29 Nov 2012

Leading allergy organizations release report that sheds light on angioedema

With today's modern medicine, misdiagnoses may be unexpected and surprising. But when symptoms of an unknown and uncommon illness mimic a number of other conditions, it can be difficult for medical professionals to properly diagnose and treat patients. That's why four leading allergy/immunology organizations have announced the release of a report to help set a new standard for a commonly misdiagnosed, under-recognized and under treated condition known as angioedema, the rapid swelling of deep layers of skin and tissue.

9 Nov 2012

Canadian Cardiovascular Society issues new pediatric heart failure guidelines

The Canadian Cardiovascular Society is the first in Canada to issue guidelines aimed at helping primary care and emergency physicians, as well as specialists, recognize and manage heart failure in children. The guidelines were released today at the Canadian Cardiovascular Congress.

30 Oct 2012

Gender gap in myocardial infarction mortality

Women are more likely to die from a myocardial infarction than men, according to research presented at the Acute Cardiac Care Congress 2012. The gender gap in mortality was independent of patient characteristics, revascularisation delays and revascularisation modalities.

20 Oct 2012

New treatment target brings hope for scleroderma patients

Research presented at the European Academy of Dermatology and Venereology in Prague, Czech Republic, suggests that inhibition of the SMAD protein may be a viable therapeutic target in scleroderma patients.

1 Oct 2012

Surprising new roles for angiotensin converting enzyme

At the 1st ECRC "Franz-Volhard" Symposium on September 7, 2012 at the Max Delbr-ck Center for Molecular Medicine (MDC) in Berlin-Buch, Professor Ken Bernstein reported that in mice an excess of ACE led to a much stronger immune response than usual.

10 Sep 2012

Type 2 diabetics with normoalbuminuria more likely to develop heart problems

In individuals with type 2 diabetes, any degree of measurable urinary protein excretion—even in what is considered the normal range—increases their risk of experiencing heart problems, according to a study appearing in an upcoming issue of new study in the Journal of the American Society of Nephrology (JASN).

31 Aug 2012

Study finds decline in 30-day mortality of acute myocardial infarction with improved treatment

Improved treatment after acute myocardial infarction and less severe patient profile have reduced 30-day mortality over the past 15 years, according to research presented at ESC Congress 2012.

29 Aug 2012

Eplerenone shown to reduce cumulative heart failure hospitalisations

Pfizer Inc. (NYSE: PFE) announced results from a new post-hoc analysis of the EMPHASIS-HF trial showing statistically significant reductions in rates of cumulative heart failure (HF) hospitalisations in patients with HF treated with eplerenone compared with placebo on a background of standard optimal therapy.1 The results were presented at The European Society of Cardiology Congress (ESC) in Munich.

28 Aug 2012

Spinal cord stimulation could become novel treatment option for heart failure

Spinal cord stimulation improves heart function and could become a novel treatment option for heart failure, according to research presented at the ESC Congress 2012 today, August 25, by Professor Hung-Fat Tse from Hong Kong.

28 Aug 2012

Insulin glargine retards progression of atherosclerosis in high-risk people

A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.

27 Aug 2012

Renal denervation leads to better outcomes than standard drug treatment in patients with AHF

Renal denervation leads to better outcomes than standard drug treatment in patients with advanced heart failure, according to research presented at ESC Congress 2012. The results of the Olomouc I pilot study were presented by Dr Miloš Táborský from the University Hospital Olomouc.

27 Aug 2012

Dyax second quarter 2012 total revenues increase to $14.0 million

Dyax Corp. today announced financial results for the second quarter ended June 30, 2012.

20 Jul 2012

Why is the incidence of gout increasing?

Gout has been described by the Daily Mail as something, “usually associated with port-swilling, over-fed elderly men of the 19th century”. (1) Recent research carried out at the Boston University School of Medicine, however, has found that the incidence of gout in the US is on the rise. (2) Thus, the condition is clearly not something that only affects this stereotype.

17 Jul 2012

InvivoSciences, WUSTL to construct artificial tissue models for heart failure

The National Institutes of Health has awarded more than $2 million to a team of scientists from Washington University in St. Louis and InvivoSciences, a biotechnology startup with WUSTL roots, to construct artificial tissue models that will allow the rapid testing of new drugs for heart failure.

17 Jul 2012